Onyx plans to file carfilzomib for multiple myeloma on Phase II data
This article was originally published in Scrip
Executive Summary
Onyx Pharmaceuticals is planning to file for accelerated approval its proteasome inhibitor, carfilzomib, by the end of the year, for the treatment of multiple myeloma after it showed potentially promising results in a single-arm Phase IIb trial testing the drug as a single-agent in patients who had exhausted other options.